Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 217,273,812 papers from all fields of science
Search
Sign In
Create Free Account
exenatide
Known as:
Synthetic exendin-4
, exenatide [Chemical/Ingredient]
, Exenatide synthetic
Expand
A 39 amino acid peptide and synthetic version of exendin-4, a hormone found in the saliva of the venomous lizard Gila monster, with insulin…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
19 relations
60 ACTUAT exenatide 0.005 MG/ACTUAT Pen Injector [Byetta]
60 ACTUAT exenatide 0.01 MG/ACTUAT Pen Injector
Diabetes Mellitus, Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent
Expand
Narrower (6)
AC 2993
Bydureon
Byetta
ITCA 650
Expand
Broader (4)
Hypoglycemic Agents
Incretins
Peptides
Venoms
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
R. Holman
,
A. Bethel
,
+15 authors
Adrian F. Hernandez
New England Journal of Medicine
2017
Corpus ID: 3408156
BACKGROUND The cardiovascular effects of adding once‐weekly treatment with exenatide to usual care in patients with type 2…
Expand
Highly Cited
2012
Highly Cited
2012
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
J. Lønborg
,
N. Vejlstrup
,
+15 authors
T. Engstrøm
European Heart Journal
2012
Corpus ID: 21504717
AIMS Exenatide, a glucagon-like-peptide-1 analogue, increases myocardial salvage in experimental settings with coronary occlusion…
Expand
Highly Cited
2011
Highly Cited
2011
Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
J. Buse
,
R. Bergenstal
,
+5 authors
J. Rosenstock
Annals of Internal Medicine
2011
Corpus ID: 26917456
BACKGROUND Insulin replacement in diabetes often requires prandial intervention to reach hemoglobin A₁(c) (HbA₁(c)) targets…
Expand
Highly Cited
2009
Highly Cited
2009
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
J. Buse
,
J. Rosenstock
,
+5 authors
L. Blonde
The Lancet
2009
Corpus ID: 25135640
Highly Cited
2008
Highly Cited
2008
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
D. Klonoff
,
J. Buse
,
+5 authors
D. Maggs
Current Medical Research and Opinion
2008
Corpus ID: 1942616
BACKGROUND Exenatide, an incretin mimetic for adjunctive treatment of type 2 diabetes (T2DM), reduced hemoglobin A(1c) (A1C) and…
Expand
Review
2006
Review
2006
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
D. Drucker
,
M. Nauck
The Lancet
2006
Corpus ID: 25748028
Highly Cited
2005
Highly Cited
2005
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
R. DeFronzo
,
R. Ratner
,
Jenny Han
,
Dennis D. Kim
,
M. Fineman
,
A. Baron
Diabetes Care
2005
Corpus ID: 16614259
OBJECTIVE This study evaluates the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients…
Expand
Highly Cited
2005
Highly Cited
2005
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
D. Kendall
,
M. Riddle
,
+4 authors
A. Baron
Diabetes Care
2005
Corpus ID: 11187602
OBJECTIVE This study evaluated the effects of exenatide, a novel incretin mimetic, in hyperglycemic patients with type 2 diabetes…
Expand
Highly Cited
2004
Highly Cited
2004
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
J. Buse
,
R. Henry
,
Jenny Han
,
Dennis D. Kim
,
M. Fineman
,
A. Baron
Diabetes Care
2004
Corpus ID: 6955031
OBJECTIVE This study evaluated the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients…
Expand
Highly Cited
1999
Highly Cited
1999
Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.
Gang Xu
,
D. Stoffers
,
J. Habener
,
S. Bonner-Weir
Diabetes
1999
Corpus ID: 30071643
Diabetes is a disease of increasing prevalence in the general population and of unknown cause. Diabetes is manifested as…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE